NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Friday morning. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.60 on Friday. The stock has a 50-day simple moving average of $0.60 and a two-hundred day simple moving average of $0.63. The firm has a market capitalization of $3.49 million, a PE ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08.

Insider Buying and Selling at NovaBay Pharmaceuticals

In other NovaBay Pharmaceuticals news, major shareholder Poplar Point Capital Partners acquired 70,685 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $0.65 per share, with a total value of $45,945.25. Following the completion of the purchase, the insider now directly owns 620,685 shares in the company, valued at approximately $403,445.25. The trade was a 12.85 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 301,077 shares of company stock valued at $188,978 over the last 90 days. 0.10% of the stock is currently owned by corporate insiders.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.